Jci_page_head_homepage_01 Jci_page_head_homepage_02
Mark R. Duranski, James J.M. Greer, Andre Dejam, Sathya Jaganmohan, Neil Hogg, William Langston, Rakesh P. Patel, Shaw-Fang Yet, Xunde Wang, Christopher G. Kevil, Mark T. Gladwin, David J. Lefer
Published in Volume 115, Issue 5
J Clin Invest. 2005; 115(5):1232–1240 doi:10.1172/JCI22493
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 4

Nitrite-mediated hepatoprotection and the NO and HO-1 signaling pathways. (A) Serum AST levels after hepatic I/R injury in mice receiving saline vehicle, nitrite (48 nmol), the NO scavenger PTIO, or nitrite (48 nmol) plus PTIO. **P < 0.01 vs. vehicle. (B) Serum levels of AST in eNOS-deficient (eNOS–/–) mice receiving saline vehicle or sodium nitrite (48 nmol). (C) Serum levels of AST in mice receiving ODQ followed by nitrite (nitrite; 48 nmol) or the sGC inhibitor ODQ and in mice receiving ODQ pretreatment after nitrite (48 nmol; Nitrite + ODQ). (D) Hepatic tissue protein levels at 6 hours after ischemia determined using Western blot methods in animals subjected to sham and I/R with saline, nitrite, or nitrate. Hepatic tissue mRNA levels of HO-1 were determined using quantitative real-time RT-PCR methods in animals subjected to hepatic I/R. (E) Serum AST levels in mice treated with nitrite (48 nmol) or the HO-1 inhibitor ZnDPBG in the setting of hepatic I/R injury. (F) Serum AST and ALT levels in HO-1–/– mice treated with and without 48 nmol of nitrite.